Securities code: 688276 Securities abbreviation: Baike Biotechnology Announcement No.: 2025-006

Changchun Baike Biotechnology Co., Ltd

Announcement on the appointment of deputy general manager

The board of directors and all directors of the company guarantee that there are no false records, misleading statements or material omissions in the content of this announcement, and assume legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Changchun Baike Biotechnology Co., Ltd. (hereinafter referred to as the "Company") was held on February 24, 2025

At the third meeting of the sixth board of directors, the "Proposal on the Appointment of the Deputy General Manager of the Company" was deliberated and approved. After the review and approval of the nomination committee of the board of directors of the company, the board of directors agreed to appoint Mr. Sun Wanfeng as the deputy general manager of the company, and the term of office will be from the date of deliberation and approval of the board of directors to the date of expiration of the sixth session of the board of directors.

Up to now, Mr. Sun Wanfeng does not hold shares of the company, and there is no situation that prohibits him from serving as a senior manager of the company as stipulated in the Company Law; Have not been punished and punished by the China Securities Regulatory Commission, stock exchanges and other relevant departments, and meet the requirements of relevant laws, regulations and regulations such as the Company Law.

The curriculum vitae of Mr. Sun Wanfeng is attached.

The announcement is hereby made.

Board of Directors of Changchun Baike Biotechnology Co., Ltd

February 26, 2025

Attachment: Curriculum vitae of Mr. Sun Wanfeng

Sun Wanfeng, male, born in March 1979, is a member of the Democratic League, with a bachelor's degree, and is currently the assistant to the chairman of the company

Reason. He has successively served as a staff member of the Vaccine Department of Jilin Provincial Center for Disease Control and Prevention, the North Region Manager of Hainan Tailing Biological Products Co., Ltd., the North Region Manager of GlaxoSmithKline Pharmaceutical Co., Ltd., the North Region Director of Beijing Xiangrui Biological Products Co., Ltd., the Southern Region Director of Dalian Yalifeng Biopharmaceutical Co., Ltd., and the Sales Director and Vice President of Chengdu Kanghua Biological Products Co., Ltd.

Up to now, Mr. Sun Wanfeng does not hold any shares of the Company, and has no relationship with other shareholders and other directors, supervisors and senior management of the Company who hold more than 5% of the shares; There is no circumstance that prohibits him from serving as a senior manager of the company as stipulated in the Company Law; There is no situation that has been determined by the China Securities Regulatory Commission to be a person prohibited from entering the market and is still in the prohibition period, nor has it been publicly determined by the stock exchange to be unsuitable for serving as a senior manager of a listed company, has not been punished and punished by the China Securities Regulatory Commission, the stock exchange and other relevant departments, has not been investigated by the judicial authorities for suspected crimes or has been investigated by the China Securities Regulatory Commission for suspected violations of laws and regulations, does not belong to the dishonest executors announced by the Supreme People's Court, and complies with the "Company Law" and other relevant laws. Conditions of appointment required by regulations and regulations.